GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) » Definitions » Cash Flow from Financing

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Cash Flow from Financing : ¥-953 Mil (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Harbin Gloria Pharmaceuticals Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Harbin Gloria Pharmaceuticals Co paid ¥0 Mil more to buy back shares than it received from issuing new shares. It spent ¥250 Mil paying down its debt. It paid ¥0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent ¥6 Mil paying cash dividends to shareholders. It received ¥90 Mil on other financial activities. In all, Harbin Gloria Pharmaceuticals Co spent ¥165 Mil on financial activities for the three months ended in Mar. 2024.


Harbin Gloria Pharmaceuticals Co Cash Flow from Financing Historical Data

The historical data trend for Harbin Gloria Pharmaceuticals Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Gloria Pharmaceuticals Co Cash Flow from Financing Chart

Harbin Gloria Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -263.95 -1,656.01 361.59 -212.55 -889.16

Harbin Gloria Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101.26 -400.68 -208.89 -178.33 -164.99

Harbin Gloria Pharmaceuticals Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Harbin Gloria Pharmaceuticals Co's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Harbin Gloria Pharmaceuticals Co's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-953 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harbin Gloria Pharmaceuticals Co  (SZSE:002437) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Harbin Gloria Pharmaceuticals Co's issuance of stock for the three months ended in Mar. 2024 was ¥0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Harbin Gloria Pharmaceuticals Co's repurchase of stock for the three months ended in Mar. 2024 was ¥0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Harbin Gloria Pharmaceuticals Co's net issuance of debt for the three months ended in Mar. 2024 was ¥-250 Mil. Harbin Gloria Pharmaceuticals Co spent ¥250 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Harbin Gloria Pharmaceuticals Co's net issuance of preferred for the three months ended in Mar. 2024 was ¥0 Mil. Harbin Gloria Pharmaceuticals Co paid ¥0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Harbin Gloria Pharmaceuticals Co's cash flow for dividends for the three months ended in Mar. 2024 was ¥-6 Mil. Harbin Gloria Pharmaceuticals Co spent ¥6 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Harbin Gloria Pharmaceuticals Co's other financing for the three months ended in Mar. 2024 was ¥90 Mil. Harbin Gloria Pharmaceuticals Co received ¥90 Mil on other financial activities.


Harbin Gloria Pharmaceuticals Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Harbin Gloria Pharmaceuticals Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Gloria Pharmaceuticals Co (SZSE:002437) Business Description

Traded in Other Exchanges
N/A
Address
Beijing Road No 29, Harbin Economic and Technological Development Zone, Harbin, CHN, 150025
Harbin Gloria Pharmaceuticals Co Ltd is a tech biopharmaceutical enterprise. It is engaged in the research, development, production, and sale of pharmaceutical products primarily in China. The company offers cardiovascular drugs; cardiac cerebrovascular medication; vitamins and minerals; urinary tract drugs; urinary system medication; anti-tumor medication; endocrine system drugs; anti-infective drugs; digestive system medication; respiratory medication; and other medications.
Executives
Guo Yun Pei Independent director
Wang Yu Supervisors
Yang Hong Bing Director
Diao Xiu Qiang Directors, executives
Liu Yue Yin Securities Affairs Representative
Guo Lei Feng Directors, Directors, and Executives
Li Jun Ling Director
Yang Hai Feng Executives
Zhang Su Mei Supervisors
Zhu Ji Man Director

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Headlines

No Headlines